CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BridgeBio Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BridgeBio Pharma Inc
3160 Porter Dr., Suite 250
Phone: (650) 391-9740p:650 391-9740 PALO ALTO, CA  94304  United States Ticker: BBIOBBIO
Business Summary
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Financial Officer ThomasTrimarchi 39 3/17/2025 7/23/2024
Chief Executive Officer, Director NeilKumar 42 7/23/2024 4/1/2015
Lead Director, Chairman of Pharmaceuticals Charles J.Homcy 75 2/1/2020 11/1/2018
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Eidos Therapeutics Inc 101 Montgomery St Ste 2550 San Francisco CA United States

Business Names
Business Name
Adrenas Therapeutics, Inc.
Audition Therapeutics, Inc.
BB Square Capital Investors I, LP
36 additional Business Names available in full report.

General Information
Number of Employees: 725 (As of 12/31/2024)
Outstanding Shares: 190,188,626 (As of 2/13/2025)
Shareholders: 46
Stock Exchange: NASD
Fax Number: (302) 655-5049


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 28, 2025